Impax launches generic version of Kadian (morphine sulfate) extended release capsules, USP CII.
Impax Laboratories, Inc., a specialty pharmaceutical company, announced the launch of a generic version of Kadian (morphine sulfate) extended release capsules, USP CII 20, 30, 50, 60, 80, 100 mg.
Morphine sulfate extended release capsules had annual combined brand and generic sales of approximately $98.4 million in the United States, according to IMS Health (NSP) for 12 months ending October 2016.
Morphine sulfate extended-release capsules, USP are an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release capsules, USP are designed for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine sulfate extended-release capsules, USP are not indicated as an as-needed (prn) analgesic.
Impax Laboratories, Inc. is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division.
Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. www.impaxlabs.com.
(Source: PR Newswire)
Filed Under: Drug Discovery